The Central Drugs Laboratories identified 60 drug samples as 'not of standard quality' in February, while state labs found 134 substandard samples. Investigations are underway for spurious drugs manufactured by unauthorised companies.
Karnataka Health Minister U T Khader announced the busting of a major interstate counterfeit drug racket, leading to an arrest and an ongoing investigation into the suspected supply of fake medicines to hospitals. The racket involved procuring cheap drugs, refilling them, and relabelling them as premium brands, with seizures worth Rs 5 crore. A Special Investigation Team (SIT) has been formed to probe the widespread network.
Indian drug regulatory and law enforcement agencies have stepped up their efforts against the illegal manufacture and distribution of spurious drugs. This intensified action follows the seizure of a "misbranded" batch of Abhayrab rabies vaccine in Delhi, prompting nationwide vigilance and arrests.
The Centre has allowed companies to begin lab testing immediately after filing applications instead of waiting for detailed scrutiny, in a move to expedite approvals for manufacture, or import of new drugs.
India's apex drug regulator cautioned against antibiotic self-medication and their use for conditions where antibiotic treatment is not clinically indicated, particularly viral infections, the common cold and fever.
SCTIMST and Invasive Technologies have launched "Chitra Core," a new drug-eluting coronary stent designed with significantly less metal to reduce complications. This indigenous innovation, developed in collaboration, aims to provide advanced and cost-effective cardiac care, building on decades of Indian medical device development. The institute is also developing a unique TiN-coated stent for global markets.
Authorities in Gurugram have uncovered a racket involving the manufacturing and sale of counterfeit Mounjaro (tirzepatide) injections, used for treating type 2 diabetes and aiding weight loss, leading to the arrest of two individuals and a nationwide alert.
CDSCO has warned consumers against using two unauthorised Pakistani whitening creams after finding excessive heavy metals and regulatory violations.
A new law is being proposed to grant statutory powers to the Central Drugs Standard Control Organisation to regulate the manufacture, distribution, and sale of drugs, medical devices, and cosmetics.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.
The World Health Organization has requested information from the Indian government regarding the alleged supply of spurious oxytocin injections linked to the deaths of five women in Kota hospitals. This comes after regulatory action, including the cancellation of manufacturing licenses for Jackson Laboratories units, following joint inspections by drug control bodies. The government is investigating the matter, emphasising a zero-tolerance approach to quality violations.
Among the commonly used analgesic formulations (painkillers) found NSQ are combinations of paracetamol with ibuprofen, diclofenac and mefenamic acid. Medications using these combinations are commonly used to treat fever, mild migraine, period and muscle pain.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
Delhi Police have arrested four individuals involved in an interstate racket manufacturing and distributing counterfeit prescription drugs, uncovering an illegal processing unit in Delhi.
The Central Drugs Standard Control Organisation (CDSCO) has initiated a nationwide campaign to test, inspect, and audit cough syrup manufacturers following concerns about contaminated products and child deaths. The initiative aims to ensure adherence to safety standards and regulatory compliance.
The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
The Central Drugs Standard Control Organisation (CDSCO) will conduct testing, inspection and auditing of cough syrup manufacturers.
The Delhi High Court has declined to halt the Centre's HPV immunisation campaign, noting that data on 5.5 million administered vaccines showed no 'instant harm'. However, the court emphasised that 'half-baked vaccines' should not be given to the public and raised 'serious issues' regarding past protocol violations in vaccine testing and certification.
India's drug regulator CDSCO has recalled three cough syrups and halted their production after the WHO raised concerns about potential contamination and links to child deaths. The WHO is investigating reports of pediatric illnesses and deaths in India potentially linked to contaminated syrups.
Following the death of 22 children due to consumption of contaminated cough syrups in Madhya Pradesh three months ago, the Union health ministry has proposed amendments in the country's drug rules to ensure a tougher criterion for their over-the-counter (OTC) sales in India.
The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation, the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the 'combination drugs' as they are 'unnecessary' and may pose health hazards. The Drugs Controller General of India had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007.
Tamil Nadu has formed special teams to monitor drug manufacturers after deaths of infants in Madhya Pradesh were linked to a cough syrup made by a Tamil Nadu-based company. Inspections are being conducted at pharmaceutical firms across the state.
It was also found at many places that spurious medicines, particularly Ayurvedic medicines, are being manufactured without licence from the competent authority.
The Central Drugs Standard Control Organisation (CDSCO), the apex drug regulator, may soon ban the production and sale of three medicines in the country. The drugs - cisapride, phenylpropanolamine (PPA) and human placenta extracts - have been controversial medicines for their alleged adverse reactions for several years now.
The government on Sunday gave a strong push to upgradation and expansion of healthcare infrastructure, medical education and pharma sector with the Union Budget 2026-27 announcing a slew of steps, including those aimed at making India a global hub for allied healthcare professionals and biopharma manufacturing.
These brands belong to about 320 drugs of leading Indian pharmaceutical companies. The Drug Controller General of India's (DCGI's) office feels that these have been launched without its approval.
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
Of the 137,000 drug government tested 345 turned out to be fake.
The Enforcement Directorate (ED) raided premises linked to Sresan Pharmaceuticals, the manufacturer of Coldrif cough syrup linked to the deaths of children in Madhya Pradesh and Rajasthan, and top officials of the Tamil Nadu FDA as part of a money laundering investigation.
The World Health Organisation on Friday said that it is in touch with the Uzbek authorities about the reported deaths of 18 children after consuming contaminated cough syrup made by Noida-based Marion Biotech.
Health ministry advisory urges rational use of cough syrups in children after 11 deaths in Madhya Pradesh and Rajasthan.
Rise in raids on illicit drug manufacturing units, alongside arrests for the production, sale, or distribution of spurious or adulterated drugs.
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
Police have arrested a doctor for alleged negligence and registered a case against the manufacturer of a 'toxic' cough syrup after the death of 14 children in Chhindwara due to suspected renal failure, officials said on Sunday.
The regulator had issued alerts in June and July of 2015.
The inspection at Marion Biotech started at around 12 pm and continued for over 10 hours during which six more samples of the syrup were taken, they said.
The joint inspections is to ensure the safety, efficacy, and quality of drugs available in the country
